No A+, but AAC Passes Pfizer's First-in-Class JAK Inhibitor
By Mari Serebrov
Thursday, May 10, 2012
An FDA advisory committee gave Pfizer Inc.'s tofacitinib passing grades as an arthritis treatment Wednesday, but it piled on the homework.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.